EmailFacebookLinkedInTwitterGoogle+
Targeting Unmet Needs in Cancer with Antibody-Drug Conjugates
Targeting Unmet Needs in Cancer with Antibody-Drug Conjugates

About US
about_us

At Oxford BioTherapeutics we are developing revolutionary antibody-drug conjugates for cancer. These have the potential to enhance treatment effectiveness while sparing healthy tissue and reducing side effects. Unlocking the power of these treatments requires precision. Precision targeting, precision delivery and precision cancer eradication. Our mission is simple: to transform patients’ lives with Precision Cancer Therapy.

read_more

We are developing precision cancer therapies

Technologies
technologies

Oxford BioTherapeutics’ world-class OGAP® technology has the power to precisely target the delivery of antibody-based cancer medicines. By combining OGAP with a range of proven antibody and chemotherapy technologies we have built a unique platform for developing novel antibody-drug conjugates to treat cancer.

read_more

Our therapies incorporate leading technologies

Pipeline
pipeline

Oxford BioTherapeutics is developing antibody-drug conjugates targeting a wide variety of cancers that are difficult to treat and consequently have significant unmet medical needs. We have a strong pipeline of in-house development programs, and work closely with a range of partners to ensure we incorporate leading technologies into our revolutionary new treatments.

read_more

We are targeting a range of cancers

Latest News
  • 14/01/2015 - Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization...

    download_pdf
  • 25/11/2014 - $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study...

    download_pdf
  • 02/10/2014 - Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate...

    download_pdf
  • 14/01/2015 - Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization...

read_more_press_releases
  • 25/11/2014 - $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study...

read_more_press_releases
  • 02/10/2014 - Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate...

read_more_press_releases
Latest News
  • 14/01/2015 Oxford BioTherapeutics Grants an Exclusive License to Boehringer Ingelheim for Development and Commercialization...

    download_pdf
  • 25/11/2014 $1 Billion Oncology Alliance between Menarini Group & Oxford BioTherapeutics Initiates First-in-Human Study...

    download_pdf
  • 02/10/2014 Oxford BioTherapeutics and Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate as Second Clinical Development Candidate...

    download_pdf